Logotype for Krystal Biotech Inc

Krystal Biotech (KRYS) Study Result summary

Event summary combining transcript, slides, and related documents.

Logotype for Krystal Biotech Inc

Study Result summary

8 Jul, 2026

Program Overview and Technology

  • KB301 is a gene therapy candidate delivering COL3A1 via a non-integrating HSV-1 vector to restore type III collagen, targeting skin rejuvenation and reversing age-related collagen decline.

  • The platform enables delivery of multiple genes, aiming to rebuild skin structure and improve appearance, and supports future pipeline expansion targeting other extracellular matrix proteins.

  • Jeune Aesthetics, a subsidiary of Krystal Biotech, is focused on clinical development, leveraging Krystal's manufacturing and regulatory expertise.

Study Design and Objectives

  • KB301 was evaluated in PEARL-I, a multicenter, open-label, split-body study for dynamic wrinkles of the décolleté and lateral canthal lines at rest in adults up to 75 years, with no recent skin treatments in target areas.

  • Key objectives included safety and preliminary efficacy, assessed by both investigators and subjects using GAIS and SSQ.

  • Cohorts III and IV focused on lateral canthal lines at rest and dynamic wrinkles of the décolleté, both areas lacking approved injectables.

  • Dosing regimens included both low and high dose KB301, with various administration techniques explored.

Efficacy and Durability Results

  • KB301 showed clinically meaningful improvements: in the décolleté, 94% of subjects had at least a one-point improvement at two months, with 28% achieving a two-point gain; in lateral canthal lines, over 90% improved by at least one GAIS point at one month, and 75% at two months.

  • 100% of subjects in both cohorts were responders by GAIS at two months in some studies, with improvements increasing over time.

  • Improvements extended to skin texture, hydration, radiance, elasticity, and crepiness, with investigator-reported improvements in up to 94% of décolleté subjects.

  • Subject satisfaction scores remained elevated for at least 7-9 months after last dose in earlier cohorts, with durability studies showing sustained efficacy up to nine months.

  • Before-and-after images demonstrated visible reduction in wrinkles and improved skin appearance.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more